New ICD-10-PCS Codes in

191 codes were added to the 2022 ICD-10-PCS code set, effective October 1, 2021.

Displaying codes 101-191 of 191:

  • 30243D1 Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Central Vein, Percutaneous Approach
  • 3E1M48X Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach, Diagnostic
  • 3E1M48Z Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach
  • 4B00XW0 Measurement of Central Nervous Cerebrospinal Fluid Shunt using Wireless Sensor, External Approach
  • 5A1221J Performance of Cardiac Output, Continuous, Automated
  • BF150ZZ Fluoroscopy of Liver using High Osmolar Contrast
  • BF151ZZ Fluoroscopy of Liver using Low Osmolar Contrast
  • BF15YZZ Fluoroscopy of Liver using Other Contrast
  • BF15ZZA Fluoroscopy of Liver, Guidance
  • X2CP3T7 Extirpation of Matter from Abdominal Aorta using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CQ3T7 Extirpation of Matter from Right Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CR3T7 Extirpation of Matter from Left Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CS3T7 Extirpation of Matter from Right Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CT3T7 Extirpation of Matter from Left Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CU3T7 Extirpation of Matter from Right Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CV3T7 Extirpation of Matter from Left Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2CY3T7 Extirpation of Matter from Great Vessel using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
  • X2JAX47 Inspection of Heart using Transthoracic Echocardiography, Computer-aided Guidance, New Technology Group 7
  • X2KB317 Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
  • X2KC317 Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
  • X2RX0N7 Replacement of Thoracic Aorta, Arch using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
  • X2V73Q7 Restriction of Coronary Sinus with Reduction Device, Percutaneous Approach, New Technology Group 7
  • X2VW0N7 Restriction of Thoracic Aorta, Descending using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
  • XD2G4V7 Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
  • XD2G8V7 Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XD2H4V7 Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
  • XD2H8V7 Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XDPH8K7 Irrigation of Lower GI using Intraoperative Single-use Oversleeve, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XFJB8A7 Inspection of Hepatobiliary Duct using Single-use Duodenoscope, New Technology Group 7
  • XFJD8A7 Inspection of Pancreatic Duct using Single-use Duodenoscope, New Technology Group 7
  • XHRPXF7 Replacement of Skin with Bioengineered Allogeneic Construct, External Approach, New Technology Group 7
  • XNS00C7 Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
  • XNS03C7 Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
  • XNS40C7 Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
  • XNS43C7 Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
  • XRGA0R7 Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGA3R7 Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGA4R7 Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGB0R7 Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGB3R7 Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGB4R7 Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGC0R7 Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGC3R7 Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGC4R7 Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGD0R7 Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGD3R7 Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGD4R7 Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XW00X27 Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7
  • XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW01X27 Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
  • XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03367 Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03377 Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03387 Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033B7 Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04367 Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04377 Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04387 Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043B7 Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW0V0P7 Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
  • XW133D7 Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW133E7 Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW143D7 Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW143E7 Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XWHD7Q7 Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7
  • XXE0X07 Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7
  • XXE3X27 Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7
  • XXE5XR7 Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
  • XXE5XT7 Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7
  • XXE5XV7 Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7
  • XXE97U7 Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7
  • XY0YX37 Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7